PRKCI: A Potential Drug Target and Biomarker for Protein Kinase C iota Type

Target Name: PRKCI

NCBI ID: G5584

PRKCI

PRKCI: A Potential Drug Target and Biomarker for Protein Kinase C iota Type

Introduction

Protein kinase C (PKC) is a family of enzymes that play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress responses. The PKC iota type is a subfamily of PKC that is involved in various cellular processes, including cell signaling, neurotransmission, and pain perception. PRKCI, also known as protein kinase C iota, is a non-catalytic subunit of PKC that is expressed in various tissues and cells.

PRKCI functions as a negative regulator of PKC, which means that it inhibits the activity of PKC. This inhibition prevents PKC from activating and activating target proteins, leading to the inhibition of cellular signaling pathways. PRKCI has been shown to play a crucial role in various cellular processes, including cell signaling, neurotransmission, and pain perception.

Drug Targeting and Biomarkers

PRKCI is a potential drug target for various diseases, including neurodegenerative disorders, pain, and cancer. The inhibition of PRKCI activity has been shown to be effective in treating various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain.

One of the main advantages of PRKCI as a drug target is its specificity. PRKCI is a non-catalytic subunit, which means that it does not have the ability to catalyze chemical reactions, making it a more targeted and less invasive treatment option. Additionally, PRKCI is a protein that is expressed in various tissues and cells, which makes it a more accessible target for drug development.

PRKCI has also been shown to be a potential biomarker for various diseases, including neurodegenerative disorders and cancer. The levels of PRKCI have been shown to be reduced in individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, the inhibition of PRKCI activity has been shown to reduce the growth and spread of cancer cells.

Targeting PRKCI

PRKCI is a potential drug target that can be targeted using various techniques, including inhibition of protein synthesis, inhibition of protein degradation, and inhibition of protein-protein interactions. One of the most promising strategies for targeting PRKCI is the use of small molecules, such as inhibitors of protein synthesis or inhibitors of protein degradation.

In inhibition of protein synthesis, small molecules such as streptomycin, a common antibiotic, have been shown to be effective in treating neurodegenerative disorders. Additionally, inhibitors of protein degradation, such as benzimidazole, have also been shown to be effective in treating neurodegenerative disorders. disorders.

In inhibition of protein-protein interactions, small molecules such as inhibitors of tyrosine kinase have been shown to be effective in treating neurodegenerative disorders. Additionally, inhibitors of voltage-gated ion channels, which are involved in neurotransmission, have also been shown to be effective in treating chronic pain.

Conclusion

PRKCI is a non-catalytic subunit of the protein kinase C family that is involved in various cellular processes. Its functions as a negative regulator of PKC and as a potential drug target for neurodegenerative disorders, pain, and cancer make PRKCI a promising target for future drug development. The inhibition of PRKCI activity has been shown to be effective in treating various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. Additionally, PRKCI has also been shown to be a potential biomarker for neurodegenerative disorders and cancer . Further research is needed to fully understand the potential of PRKCI as a drug target and biomarker.

Protein Name: Protein Kinase C Iota

Functions: Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation (By similarity)

The "PRKCI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKCI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets